An anti-phosphatidylserine antibody test detects autoantibodies that react with phosphatidylserine, a membrane phospholipid that becomes exposed when cells are activated, injured, or undergoing programmed death. The test may be ordered as part of an extended antiphospholipid antibody evaluation for unexplained blood clots, recurrent pregnancy complications, lupus, or symptoms that resemble antiphospholipid syndrome despite negative standard tests.
Anti-phosphatidylserine antibodies are not included among the laboratory markers used in current APS classification criteria. A positive result can support clinical suspicion in selected cases, but it cannot establish APS by itself. Interpretation is also complicated by differences between assays that measure antibodies to phosphatidylserine alone and assays that measure antibodies to a phosphatidylserine-prothrombin complex. These tests are related but not interchangeable. The most useful interpretation combines the exact test name, IgG or IgM class, result strength, repeat results, standard APS antibodies, and a documented history of thrombosis or qualifying pregnancy morbidity.
- The test usually reports IgG and IgM antibodies directed against phosphatidylserine-containing targets.
- A positive result is a non-criteria finding and does not independently diagnose antiphospholipid syndrome.
- Anti-phosphatidylserine and anti-phosphatidylserine/prothrombin are different assays with different clinical evidence.
- There is no universal normal range; use the cutoff and units printed by the performing laboratory.
- A weak isolated result may be temporary and often carries less weight than persistent, multi-antibody positivity.
- Sudden chest pain, shortness of breath, one-sided swelling, weakness, or speech difficulty requires urgent assessment for thrombosis.
Table of Contents
- Phosphatidylserine and the Antibodies Being Measured
- Anti-Phosphatidylserine Versus aPS/PT Testing
- Why Clinicians Order the Test
- How to Interpret Positive, Borderline, and Negative Results
- Relationship to APS and Clotting Risk
- Meaning in Pregnancy and Recurrent Loss
- Blood Collection, Interference, and Repeat Testing
- What to Do After a Positive Result
Phosphatidylserine and the Antibodies Being Measured
Phosphatidylserine is a negatively charged phospholipid that normally stays mainly on the inner surface of a cell membrane. Enzymes maintain that asymmetry. When platelets activate, cells become damaged, or cells enter apoptosis, phosphatidylserine can move to the outer membrane surface. Its exposure helps assemble coagulation proteins and supports normal clot formation at an injury site.
The immune system may produce antibodies that recognize phosphatidylserine or proteins attached to a phosphatidylserine-rich surface. These autoantibodies are grouped broadly with antiphospholipid antibodies, even though many clinically important antibodies bind phospholipid-associated proteins rather than the lipid alone.
Most commercial anti-phosphatidylserine assays are solid-phase immunoassays. A laboratory places phosphatidylserine-containing antigen on a plate, adds patient serum, and measures antibody binding. Reports commonly separate:
- IgG anti-phosphatidylserine, which may receive more clinical attention when the level is substantial and persistent;
- IgM anti-phosphatidylserine, which can occur transiently and must be judged in context;
- IgA anti-phosphatidylserine, which is less widely offered and less well validated.
The result may appear as units per milliliter, an index value, a ratio, or qualitative wording such as negative, equivocal, or positive. There is no internationally harmonized calibrator. One laboratory’s “moderate positive” may not equal another laboratory’s result at the same number.
Why a universal range is not available
Routine blood tests such as sodium or glucose use highly standardized measurement systems. Anti-phosphatidylserine assays do not yet have that level of harmonization. Manufacturers may use different lipid preparations, plate surfaces, buffers, calibrators, and healthy-control populations. Some laboratories set a cutoff at a percentile of local control samples; others follow the kit manufacturer’s interval.
This means a number should never be detached from its report. A value described as 18 units could be negative in one method and positive in another. Even the labels “weak,” “moderate,” and “strong” may have different boundaries. The safest way to compare results is to use the same laboratory and retain the full report. Converting values between assays is generally not valid.
Age, sex, and pregnancy do not have established separate aPS reference ranges. The absence of a universal range is not evidence that every detected antibody is dangerous; it is a reason to rely more heavily on the clinical setting and standardized APS tests.
The biological presence of phosphatidylserine does not mean every antibody against it is pathogenic. Some antibody binding may reflect a temporary immune response, background autoreactivity, or assay-specific behavior. Clinical relevance becomes more plausible when the result is reproducible, clearly above the cutoff, accompanied by other antiphospholipid antibodies, and linked to a compatible event.
Anti-Phosphatidylserine Versus aPS/PT Testing
The test name must be read carefully because “phosphatidylserine antibody” is sometimes used loosely. A direct anti-phosphatidylserine assay and an anti-phosphatidylserine/prothrombin assay do not measure the same target.
| Test | Main target | Current clinical position |
|---|---|---|
| Anti-phosphatidylserine | Phosphatidylserine or assay-dependent phosphatidylserine structures | Non-criteria marker with variable methods and limited standardization |
| Anti-phosphatidylserine/prothrombin, or aPS/PT | A complex formed by phosphatidylserine and prothrombin | Non-criteria marker with a larger evidence base, especially for lupus anticoagulant association and thrombosis risk |
| Anti-prothrombin | Prothrombin presented without the same phosphatidylserine complex | Non-criteria marker; assay performance and associations differ from aPS/PT |
Prothrombin is a clotting protein that can bind anionic phospholipid surfaces. In an aPS/PT assay, phosphatidylserine helps present prothrombin in a conformation recognized by certain autoantibodies. Those antibodies correlate more strongly with lupus anticoagulant in many studies than antibodies against phosphatidylserine alone.
This distinction prevents a common error: assuming that a positive anti-phosphatidylserine result carries the same evidence as a positive phosphatidylserine-prothrombin antibody test. It does not. The exact antigen, manufacturer, antibody class, and reference interval should be visible on the report. When the wording is unclear, the ordering clinician can ask the laboratory whether prothrombin was included in the assay.
Extended panels may list both tests. A person can be positive on one and negative on the other because the recognized structures differ. Results should not be added together as if they were interchangeable measurements of one antibody.
Why Clinicians Order the Test
Anti-phosphatidylserine testing is usually a second-line or specialist test. The standard APS laboratory evaluation remains lupus anticoagulant, anticardiolipin IgG and IgM, and anti-beta-2 glycoprotein I IgG and IgM.
A clinician may consider an extended test when a patient has:
- a confirmed unprovoked venous clot, arterial clot, or clot in an unusual site;
- recurrent early pregnancy losses or a later fetal death with no clear explanation;
- severe placental insufficiency, fetal growth restriction, or early severe preeclampsia;
- livedo reticularis, low platelets, heart-valve abnormalities, or other APS-associated features;
- systemic lupus erythematosus and a concerning vascular or obstetric history;
- repeatedly negative criteria antibodies despite a pattern strongly suggestive of APS;
- conflicting or incomplete prior laboratory results that require specialist review.
The test is not a general screening test for healthy people. Broad testing in a low-risk population produces more incidental positives because the chance that an abnormal result represents disease depends on the pretest probability. A weak positive in someone with no clot, no pregnancy morbidity, and no autoimmune disease has a different meaning from the same result in someone with an objectively confirmed stroke and other positive antiphospholipid markers.
Testing may also be inappropriate when it will not change management. For example, a patient already receiving lifelong anticoagulation for a clearly defined reason may gain little from an unstandardized marker unless a specialist needs it to clarify diagnosis, pregnancy planning, or family counseling.
An extended seronegative antiphospholipid syndrome panel can include several non-criteria antibodies, but no panel result should substitute for careful verification of the clinical event.
How to Interpret Positive, Borderline, and Negative Results
The laboratory category is only the starting point. Interpretation should answer five questions: what antigen was used, which immunoglobulin class was positive, how high the result was, whether it persisted, and whether the patient has a compatible clinical history.
Positive result
A positive result means antibody binding exceeded the laboratory’s threshold. It may reflect genuine autoimmunity, transient immune activation, or assay-specific reactivity. A positive test alone does not show that the antibody caused a clot or pregnancy complication.
Higher values often attract more attention than values just above the cutoff, but anti-phosphatidylserine testing lacks a validated universal relationship between titer and risk. Terms such as low, moderate, and high apply only to the laboratory’s own method unless the manufacturer has defined categories.
Borderline or equivocal result
A borderline result lies close to the cutoff, where analytical variation has greater influence. Repeating the same sample, obtaining a later sample, or using the same laboratory may help clarify whether the finding is reproducible. A borderline value should not be rounded up to “positive APS.”
Negative result
A negative anti-phosphatidylserine result means the assay did not detect antibodies above its threshold. It does not rule out APS because anti-phosphatidylserine is not a required criteria marker. It also does not exclude aPS/PT antibodies, lupus anticoagulant, anticardiolipin, or anti-beta-2 glycoprotein I.
Isolated versus combined positivity
An isolated weak result generally carries less weight than a persistent result found alongside criteria antibodies. Risk assessment in APS is driven strongly by the criteria profile, especially lupus anticoagulant and triple positivity. Combined antibody patterns may indicate a broader autoimmune response, but anti-phosphatidylserine does not automatically raise a patient into a defined high-risk category.
| Pattern | How it is usually viewed |
|---|---|
| Single low-positive anti-phosphatidylserine result | Low specificity; review timing, illness, assay, and pretest probability |
| Persistent anti-phosphatidylserine without criteria antibodies | May support specialist evaluation but remains insufficient for criteria APS |
| Anti-phosphatidylserine plus positive criteria antibodies | May reflect broader antibody reactivity; management remains based mainly on criteria results and clinical events |
| Anti-phosphatidylserine positive, aPS/PT negative | Shows that the assays are detecting different targets; do not infer aPS/PT-associated risk |
| Negative anti-phosphatidylserine with positive lupus anticoagulant | APS risk can still be clinically important because anti-phosphatidylserine is not required |
Relationship to APS and Clotting Risk
Antiphospholipid syndrome is an autoimmune thrombo-inflammatory disorder defined clinically by thrombosis, pregnancy morbidity, or other recognized manifestations together with persistent, relevant antiphospholipid antibodies. Classification criteria are written primarily to create consistent research groups. Clinical diagnosis still requires judgment, but non-criteria antibodies should not be treated as if they have the same validation as criteria tests.
The 2023 ACR/EULAR classification criteria use weighted clinical and laboratory domains. Their laboratory components focus on lupus anticoagulant and solid-phase IgG or IgM anticardiolipin and anti-beta-2 glycoprotein I antibodies. Direct anti-phosphatidylserine antibodies are not included.
Research has associated some non-criteria antiphospholipid antibodies with thrombosis. The evidence is strongest and most consistent for certain targets, especially aPS/PT, rather than for every phospholipid antibody sold in an extended panel. Studies of direct anti-phosphatidylserine antibodies vary in population, method, and outcome, which limits a precise estimate of clot risk.
A clotting event should be documented objectively. Examples include ultrasound-confirmed deep vein thrombosis, imaging-confirmed pulmonary embolism, brain imaging showing ischemic stroke, or vascular imaging confirming arterial thrombosis. Symptoms alone cannot establish the event, and superficial bruising or a prolonged clotting test is not the same as thrombosis.
The patient’s broader risk environment matters. Surgery, immobility, cancer, estrogen, pregnancy, the postpartum period, smoking, obesity, age, inherited thrombophilia, and cardiovascular disease can contribute to a clot. Antiphospholipid antibodies may be one part of a “multiple-hit” process rather than a single sufficient cause.
People with symptoms of a new clot need medical evaluation regardless of their antibody status. A normal anti-phosphatidylserine test must never delay imaging or emergency treatment when clinical suspicion is high.
Meaning in Pregnancy and Recurrent Loss
Phosphatidylserine-related antibodies have been studied in recurrent miscarriage, fetal death, preeclampsia, placental insufficiency, and preterm birth. Potential mechanisms include altered trophoblast function, placental inflammation, complement activation, and interference with coagulation on placental cell surfaces. These mechanisms remain under investigation.
A positive direct anti-phosphatidylserine test does not prove that an antibody caused a miscarriage. Early pregnancy loss has many causes, with fetal chromosome abnormalities being common in sporadic losses. Uterine abnormalities, endocrine disorders, parental chromosome rearrangements, age-related factors, and other maternal illnesses may also contribute.
The clinical pattern deserves careful reconstruction:
- number of losses and whether they were consecutive;
- gestational age at each loss;
- whether fetal cardiac activity had been documented;
- chromosome testing of pregnancy tissue when available;
- placental pathology and evidence of infarction or poor perfusion;
- maternal blood pressure and timing of preeclampsia;
- fetal growth measurements;
- results of all criteria antiphospholipid tests;
- treatment used in prior pregnancies and the outcome.
Studies of aPS/PT have generally produced more clinically persuasive pregnancy data than studies of antibodies against phosphatidylserine alone. That distinction should remain visible in counseling. A positive direct anti-phosphatidylserine result may justify a specialist discussion, but it does not create a validated indication for aspirin or heparin.
For people who fulfill accepted obstetric APS criteria, low-dose aspirin and prophylactic heparin are commonly used in pregnancy under medical supervision. Evidence is much less certain for isolated non-criteria antibodies. Treatment exposes the patient to bleeding, bruising, heparin reactions, and other complications, so the expected benefit must be individualized.
A complete APS blood test panel is more informative than relying on one extended marker. Maternal-fetal medicine, hematology, and rheumatology may need to coordinate when the history is complex.
Blood Collection, Interference, and Repeat Testing
The test requires a blood draw from a vein. Fasting is generally not required. Patients should provide a complete medication list and mention recent infection, vaccination, surgery, pregnancy, or autoimmune flare because these details can affect interpretation even if they do not directly interfere with the assay.
Anticoagulants are a major concern for lupus anticoagulant testing because they change clotting times. Solid-phase antibody assays such as anti-phosphatidylserine are less directly affected, but patients must not stop warfarin, heparin, or a direct oral anticoagulant without explicit instructions. The danger from interrupting anticoagulation can outweigh any laboratory benefit.
Sample quality can matter. Severe hemolysis, lipemia, contamination, poor storage, or repeated freeze-thaw cycles may affect immunoassays. Specialty testing is often sent to a reference laboratory, so turnaround may take several days.
There is no universally mandated repeat interval for direct anti-phosphatidylserine antibodies. Clinicians often borrow the 12-week interval used for criteria antiphospholipid antibodies when they want to determine persistence. Repeating sooner may confirm a technical concern, but it does not establish long-term persistence.
For comparison over time:
- use the same laboratory and assay whenever possible;
- retain the numerical value, units, cutoff, and antibody class;
- record whether the sample was drawn during acute illness or pregnancy;
- repeat criteria antibodies according to accepted APS testing principles;
- avoid serial testing when the result will not change care.
The purpose of repeat measurement should be stated before the blood draw. Rechecking repeatedly until one value becomes positive can create misleading “diagnoses” through normal test variation.
A repeat result can also fall into a different category without a meaningful biological change when the first value was close to the cutoff. Clinicians should look at the actual numbers, not only a switch from “equivocal” to “positive.” If a laboratory changes its assay between draws, the two values may not be comparable at all. A stable clinical history and a well-documented criteria antibody profile generally provide more reliable guidance than frequent extended-panel testing.
What to Do After a Positive Result
A positive result calls for verification and context rather than automatic anticoagulation.
- Identify the exact assay. Confirm whether the report measures phosphatidylserine alone or the phosphatidylserine/prothrombin complex.
- Review the full antibody profile. Check lupus anticoagulant, anticardiolipin IgG/IgM, and anti-beta-2 glycoprotein I IgG/IgM, including dates and titers.
- Confirm the clinical event. Obtain imaging reports for clots and detailed records for pregnancy complications.
- Assess temporary causes. Note recent infection, inflammatory illness, pregnancy, and medicines.
- Decide whether repeat testing has a purpose. Persistence may add context, but repeated non-criteria testing should not become an end in itself.
- Discuss treatment with the appropriate specialist. Hematology may lead thrombotic evaluation; maternal-fetal medicine may guide pregnancy planning; rheumatology may assess lupus or systemic autoimmunity.
Do not begin aspirin because an extended panel is positive without discussing bleeding risk and the clinical reason for treatment. Over-the-counter availability does not make aspirin harmless. It can cause gastrointestinal bleeding, worsen certain bleeding disorders, and interact with anticoagulants or anti-inflammatory drugs.
Emergency symptoms deserve immediate care: sudden shortness of breath, chest pain, coughing blood, fainting, one-sided leg swelling, new facial droop, arm weakness, speech difficulty, sudden vision loss, or a severe unfamiliar headache. In pregnancy, severe headache, visual symptoms, right-upper-abdominal pain, heavy bleeding, or reduced fetal movement also requires prompt assessment.
For a routine appointment, bring complete reports rather than screenshots that omit the assay name or reference interval. Ask whether the result changes diagnosis, prevention during surgery or pregnancy, contraceptive choices, or long-term treatment. A useful conclusion may be that the result is supportive but not actionable. That is still a clinically meaningful interpretation.
Three examples of context changing the meaning
Consider three people with the same low-positive IgM result. One has no clotting history and was tested during a viral infection. Another had an unprovoked pulmonary embolism but negative criteria antibodies. A third has lupus, persistent lupus anticoagulant, and a previous fetal death. The laboratory line is identical, yet its clinical weight is not. The first result may reasonably be viewed as incidental or temporary. The second may prompt specialist review of an extended antibody profile and other clot risks. In the third, management will be driven mainly by the established high-risk criteria profile and clinical events, with anti-phosphatidylserine serving as additional background.
This example also shows why internet interpretation by number alone is unreliable. A laboratory result is evidence, not a diagnosis. Its value rises or falls according to the quality of the clinical history, the strength and persistence of other antibodies, and whether a treatment decision depends on it.
References
- An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies 2025 (Guidance)
- The emerging value of anti-phosphatidylserine/prothrombin antibodies in the diagnosis and risk stratification of antiphospholipid syndrome 2023 (Review)
- The value of non-criteria antiphospholipid antibodies 2024 (Review)
- Criteria and Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: How Strong Are They Correlated? 2023 (Study)
- Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added 2022 (Study)
- Guidelines on the investigation and management of antiphospholipid syndrome 2024 (Guideline)
Disclaimer
This information is educational and does not diagnose antiphospholipid syndrome or determine an individual treatment plan. Direct anti-phosphatidylserine results should be interpreted with the exact assay, criteria APS tests, documented clinical events, and specialist judgment. Do not start, stop, or change aspirin or anticoagulant treatment without the prescribing clinician.
